"....Regardless though....you would think this kind of rhetoric might give RVX a boost, but perhaps its just that as a small Canadian biotech, listed on the TSX and only trading OTC in the states....that its our oft repeated complaint about lack of exposure"

I would have zero expectation of that.  It's not going to change what has to be done in BETonMACE.  Anything else is still too far out for it to affect stock price.

And long will it take the FDA to revise policies?  At least a year.  And who's to say Trump's demand for lower prices doesn't offset a speedier approval process?

RVX is not where it is because of "lack of exposure".  It's uncertainty, and  the timeline.  An eternity in short-attention-span stock market time.

(my bolding)